Sodium Oligomannate (GV-971) for Alzheimer's Disease

Overview

flowchart TD
    TNF["TNF"] -->|"associated with"| NLRP3["NLRP3"]
    TNF["TNF"] -->|"therapeutic target"| AKT1["AKT1"]
    TNF["TNF"] -->|"activates"| MTOR["MTOR"]
    TNF["TNF"] -->|"activates"| AKT["AKT"]
    TNF["TNF"] -->|"activates"| PI3K["PI3K"]
    TNF["TNF"] -->|"activates"| BDNF["BDNF"]
    TNF["TNF"] -->|"activates"| STAT3["STAT3"]
    TNF["TNF"] -->|"therapeutic target"| AKT["AKT"]
    TNF["TNF"] -->|"therapeutic target"| TP53["TP53"]
    TNF["TNF"] -->|"inhibits"| PI3K["PI3K"]
    TNF["TNF"] -->|"inhibits"| AKT["AKT"]
    TNF["TNF"] -->|"activates"| ASTROCYTES["ASTROCYTES"]
    TNF["TNF"] -->|"activates"| Tumor["Tumor"]
    TNF["TNF"] -->|"activates"| Apoptosis["Apoptosis"]
    style TNF fill:#4fc3f7,stroke:#333,color:#000

Sodium Oligomannate (GV-971, trade name: Oligomannate) is a disease-modifying therapy for Alzheimer’s disease developed by Green Valley Pharmaceuticals (Shanghai, China). It received conditional approval from the China National Medical Products Administration (NMPA) in November 2019 for the treatment of mild to moderate Alzheimer’s disease, making it the first new disease-modifying treatment approved anywhere in the world since 2003^{1Sodium oligomannate: a new therapeutic option for Alzheimer's disease2021 · Neurosci Bull · PMID 34645156Open reference2China approves GV-971, the first new drug for Alzheimer's disease in 17 years2019 · BMJ · DOI 10.1136/bmj.l6570Open reference}.

GV-971 is a marine-derived acidic oligosaccharide extracted from brown algae (Ascophyllum nodosum). Unlike previous Alzheimer’s drugs that target amyloid-beta or tau pathology directly, GV-971 takes a novel approach by modulating the gut-brain axis through alteration of gut microbiota composition

Mechanism of Action

Gut Microbiota Modulation

GV-971 operates through a distinctive gut-brain axis mechanism:

1. Gut Microbiome Alteration: GV-971 reduces pro-inflammatory gut bacteria (such as Escherichia/Shigella) while increasing beneficial bacteria (such as Bifidobacterium and Lactobacillus)^{3Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression2019 · Cell Discov · PMID 31562858Open reference}

2. Reduction of Peripheral Inflammation: By modulating gut microbiota, GV-971 decreases the levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) in the peripheral blood^{3Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression2019 · Cell Discov · PMID 31562858Open reference}

3. Neuroinflammation Reduction: Lower peripheral inflammation leads to reduced neuroinflammation in the brain through the gut-brain immune pathway^{3Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression2019 · Cell Discov · PMID 31562858Open reference}

4. Amyloid Plaque Reduction: Studies show GV-971 can reduce amyloid-beta plaque deposition in the hippocampus and cortex^{4GV-971 ameliorates amyloid-beta pathology and cognitive deficits in APP/PS1 transgenic mice2020 · Acta Pharmacol Sin · PMID 32838475Open reference}

Key Molecular Targets

• Gut microbiota: Reduces Escherichia/Shigella populations

• Peripheral cytokines: Decreases IL-1β, IL-6, TNF-α

• Brain microglia: Modulates microglial activation states

• Amyloid-beta: Reduces plaque burden in AD models

Clinical Evidence

Phase 3 Trial (Green Memory Study)

The pivotal Phase 3 trial (NCT02293915) enrolled 818 patients with mild to moderate Alzheimer’s disease (MMSE score 10-26) in China^{5Green Memory: a phase 3 trial of GV-971 in mild-to-moderate Alzheimer's disease2021 · Innovation (Camb) · PMID 34545857Open reference}:

• Study Design: 36-week, randomized, double-blind, placebo-controlled

• Dosage: 450 mg twice daily (900 mg total daily)

• Primary Endpoint: Change from baseline in ADAS-Cog score at week 36

Results:

• Significant improvement in cognitive function vs. placebo (difference: -2.15 points on ADAS-Cog at week 36, p=0.0004)

• Benefits observed as early as week 4

• Good safety profile with mostly mild adverse events

Supporting Studies

• Phase 2 Trial: Showed dose-dependent cognitive benefits with good tolerability^{6A randomized, double-blind, placebo-controlled phase II trial of GV-971 in mild-to-moderate Alzheimer's disease2018 · J Alzheimers Dis · PMID 29339073Open reference}

• Post-hoc Analyses: Suggested benefits in patients with mild to moderate AD

• Real-world Data: Chinese real-world studies have reported continued use and monitoring^{7Green Valley Pharmaceuticals - GV-971 ResearchOpen reference}

Dosing and Administration

Safety and Adverse Effects

Common Adverse Events

• Nausea (most common)

• Diarrhea

• Dizziness

• Headache

• Fatigue

Safety Profile

GV-971 demonstrated a favorable safety profile in clinical trials:

• No major organ toxicity

• Low rates of serious adverse events

• No significant differences in discontinuation rates vs. placebo

• Drug-related adverse events were mostly mild to moderate

Regulatory Status

The FDA Fast Track designation was granted in 2020 to facilitate development and expedite review^{8FDA grants Fast Track designation for GV-9712020Open reference}. Green Valley has been conducting additional clinical trials to meet international regulatory requirements.

Comparison with Other AD Therapies

Research Pipeline

Ongoing Studies

• Global Phase 3 Trials: Planning or recruiting for international trials

• Combination Therapy: Studies exploring GV-971 combined with standard AD treatments

• Biomarker Studies: Investigating predictive biomarkers for treatment response

• Mechanism Studies: Further elucidation of gut-brain signaling pathways

Future Directions

1. Biomarker Development: Identifying patients most likely to respond

2. Combination Approaches: Testing with cholinesterase inhibitors or other disease-modifying therapies

3. Early Intervention: Potential use in prodromal AD or preclinical populations

4. Mechanistic Biomarkers: Gut microbiome and inflammatory markers as treatment response predictors

See Also

• Sodium Oligomannate (GV-971) — Drug Overview

• Alzheimer’s Disease

• Gut-Brain Axis in Neurodegeneration

• Amyloid Hypothesis

• Neuroinflammation in AD

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

External Links

• ClinicalTrials.gov - GV-971 Studies

• Green Valley Pharmaceuticals

• Alzheimer’s Association - Drug Treatments